JILL KALMAN MD
Prescription History 1528034352
Internal Medicine - Cardiovascular Disease in New York, NY


Quality Rating: 91.25 out of 100 score

NPI Status: Active since February 23, 2006

Contact Information

5 E 98TH ST
3RD FLOOR
NEW YORK, NY
ZIP 10029
Phone: (212) 241-5586

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JILL KALMAN MD, an active Cardiovascular Disease specialist practicing in New York, NY. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 13 documented patient claims. Among these therapy options, the most frequently utilized medication is Entresto, which accounts for 13 claims alone.

Medication Index

No matching medications currently found on file.

Entresto

Generic Formulation: Sacubitril/ValsartanSpecialty: Cardiology
Provider Metrics Summary
Total Claims 13
30-Day Fills 34.0
Days Supply 1,020
NY State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills76.9
Peer Average Days Supply2,236
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,599.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,738.46

State Avg Cost Per Claim

$1,026.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat certain types of heart failure. It may help you live longer and lower your chance of having to go to the hospital for heart failure. This product contains 2 medications: sacubitril and valsartan. Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JILL KALMAN MD provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Cardiovascular Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.